|
🐜
|
Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.
16 auth.
P. Mclaughlin,
A. Grillo‐López,
B. Link,
R. Levy,
M. Czuczman,
Michael E. Williams,
M. Heyman,
I. Bence-Bruckler,
C. White,
F. Cabanillas,
...
V. Jain,
A. Ho,
J. Lister,
K. Wey,
D. Shen,
B. Dallaire
|
11 |
1998 |
11
🐜
|
|
🐜
|
Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma.
13 auth.
T. Witzig,
L. Gordon,
F. Cabanillas,
M. Czuczman,
C. Emmanouilides,
R. Joyce,
B. Pohlman,
N. Bartlett,
G. Wiseman,
Norman M. Padre,
...
A. Grillo‐López,
P. Multani,
C. White
|
10 |
2002 |
10
🐜
|
|
🦁
|
Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy.
10 auth.
M. Czuczman,
A. Grillo‐López,
C. White,
M. Saleh,
L. Gordon,
A. Lobuglio,
...
C. Jonas,
D. Klippenstein,
B. Dallaire,
C. Varns
|
9 |
1999 |
9
🦁
|
|
🐜
|
An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era.
19 auth.
Zheng Zhou,
L. Sehn,
A. Rademaker,
L. Gordon,
A. LaCasce,
Allison Crosby‐Thompson,
A. Vanderplas,
A. Zelenetz,
G. Abel,
M. Rodriguez,
...
A. Nademanee,
M. Kaminski,
M. Czuczman,
M. Millenson,
J. Niland,
R. Gascoyne,
J. Connors,
J. Friedberg,
J. Winter
|
9 |
2014 |
9
🐜
|
|
🐜
|
Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity.
17 auth.
W. Wilson,
O. O’Connor,
M. Czuczman,
A. LaCasce,
J. Gerecitano,
J. Leonard,
A. Tulpule,
K. Dunleavy,
H. Xiong,
Y. Chiu,
...
Yue Cui,
T. Busman,
S. Elmore,
S. Rosenberg,
A. Krivoshik,
S. Enschede,
R. Humerickhouse
|
9 |
2010 |
9
🐜
|
|
🐜
|
Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and efficacy of re-treatment.
10 auth.
T. Davis,
A. Grillo‐López,
C. White,
P. Mclaughlin,
M. Czuczman,
B. Link,
...
D. Maloney,
R. Weaver,
J. Rosenberg,
R. Levy
|
9 |
2000 |
9
🐜
|
|
🐜
|
Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma.
11 auth.
T. Witzig,
I. Flinn,
L. Gordon,
C. Emmanouilides,
M. Czuczman,
M. Saleh,
...
L. Cripe,
G. Wiseman,
T. Olejnik,
P. Multani,
C. White
|
9 |
2002 |
9
🐜
|
|
🐜
|
Association of serum Rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin's lymphoma.
10 auth.
N. Berinstein,
A. Grillo‐López,
C. White,
I. Bence-Bruckler,
D. Maloney,
M. Czuczman,
...
D. Green,
J. Rosenberg,
P. Mclaughlin,
D. Shen
|
9 |
1998 |
9
🐜
|
|
🐜
|
Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma.
11 auth.
K. Dunleavy,
S. Pittaluga,
M. Czuczman,
S. Dave,
George W. Wright,
N. Grant,
...
M. Shovlin,
E. Jaffe,
J. Janik,
L. Staudt,
W. Wilson
|
9 |
2009 |
9
🐜
|
|
🐢
|
Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase II study.
17 auth.
A. Chanan-Khan,
K. Miller,
L. Musial,
D. Lawrence,
S. Padmanabhan,
K. Takeshita,
C. Porter,
D. Goodrich,
Z. Bernstein,
P. Wallace,
...
D. Spaner,
A. Mohr,
C. Byrne,
F. Hernandez-Ilizaliturri,
C. Chrystal,
P. Starostik,
M. Czuczman
|
8 |
2006 |
8
🐢
|
|
🐜
|
Phase II study of rituximab in combination with chop chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma.
9 auth.
J. Vose,
B. Link,
M. Grossbard,
M. Czuczman,
A. Grillo‐López,
P. Gilman,
...
A. Lowe,
L. Kunkel,
R. Fisher
|
8 |
2001 |
8
🐜
|
|
🐢
|
An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin's lymphoma.
13 auth.
T. Witzig,
J. Vose,
P. Zinzani,
C. Reeder,
R. Buckstein,
J. Polikoff,
R. Bouabdallah,
C. Haioun,
H. Tilly,
P. Guo,
...
D. Pietronigro,
A. Ervin‐Haynes,
M. Czuczman
|
8 |
2011 |
8
🐢
|
|
🐜
|
Extended Rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma.
12 auth.
L. Piro,
C. White,
A. Grillo‐López,
N. Janakiraman,
A. Saven,
T. Beck,
...
C. Varns,
S. Shuey,
M. Czuczman,
J. Lynch,
J. E. Kolit,
V. Jain
|
8 |
1999 |
8
🐜
|
